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Abstract
Introduction Implantation of TheraCyte 4 9 106 live
parathyroid cells can increase the bone marrow density of
the spine of ovariectomized rats. There has been no pub-
lished study examining the effect of such implantation on
spinal fusion outcomes. The purpose of this study was to
examine the effect of TheraCyte-encapsulated parathyroid
cells on posterolateral lumbar fusions in a rat model.
Materials and methods Forty Sprague-Dawley rats
underwent single-level, intertransverse process spinal
fusions using iliac crest autograft. The rats were randomly
assigned to two groups: Group 1 rats received sham
operations on their necks (control; N = 20); Group 2 rats
were implanted with TheraCyte-encapsulated 4 9 106 live
parathyroid cells into the subcutis of their necks (Thera-
Cyte; N = 20). Six weeks after surgery the rats were killed.
Fusion was assessed by inspection, manual palpation,
radiography, and histology. Blood was drawn to measure
the serum levels of calcium, phosphorus, and intact para-
thyroid hormone (iPTH).
Results Based on manual palpation, the control group
had a fusion rate of 33 % (6/18) and the TheraCyte group
had a fusion rate of 72 % (13/18) (P = 0.044). Histology
confirmed the manual palpation results. Serum iPTH levels
were significantly higher in the TheraCyte group compared
with the control group (P \ 0.05); neither serum calcium
nor phosphorus levels were significantly different between
the two groups.
Discussion This pilot animal study revealed that there
were more fusions in rats that received TheraCyte-encap-
sulated 4 9 106 live parathyroid cells than in control rats
without significant change in serum calcium or phosphorus
concentrations. As with any animal study, the results may not
extrapolate to a higher species. Further studies are needed to
determine if these effects are clinically significant.
Keywords Animal models  TheraCyte parathyroid
cells  Lumbar fusion
Introduction
It has long been believed that good therapeutic outcomes
with regard to degenerative disease of the lumbar spine are
achieved by fusion after posterior fusion [1]. Failure to
achieve solid fusion may lead to loss of alignment, insta-
bility, pain, and potential neurologic injury. Augmentation
with autologous bone graft is the current gold standard pro-
cedure to achieve lumbar solid fusion [2]. However, use of
autograft is limited by supply and there is significant donor
site morbidity [3]. Many attempts have been undertaken to
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minimize the need to harvest autograft and maximize the
effect of autograft or bone graft alternatives. A potential
alternative for facilitating fusion is the administration of
systemic medication that has known anabolic effects on
bone. Parathyroid hormone (PTH) is one such candidate
protein. Daily injection appears to induce a net increase in
bone formation [2–6], assist fracture healing [7–9], and
facilitate bone formation and fusion rates in the rat pos-
terolateral lumbar fusion model [10, 11]. However, daily
injection of PTH is inconvenient and troublesome. Another
option is transplantation of parathyroid tissues, but the main
obstacle with this option is immunological rejection [12, 13].
We as well as others have found that using a microencap-
sulate of human parathyroid cells significantly increase PTH
secretion in vitro and in rats without pharmacological
immunosuppression [14–16]. Following the implantation of
TheraCyte-encapsulated parathyroid cells in rats, we found
that the parathyroid cells could survive and secrete intact
PTH (iPTH) for up to 3 months [14]. No lymphocyte infil-
tration was found within the TheraCyte device. Implantation
of TheraCyte 4 9 106 live parathyroid cells can function
very well and increase bone marrow density (BMD) in the
lumbar spine for up to 3 months or longer. There has been no
published study examining its effect on spinal fusion out-
comes. The purpose of this study is to examine the effect of
TheraCyte-encapsulated parathyroid cells on posterolateral
lumbar fusion in a rat model.
Materials and methods
Forty Sprague-Dawley rats approximately 10 weeks of age
and 220–280 g in weight were selected for this study. Anes-
thesia was induced with ketamine and xylocaine intraperito-
neally, and perioperative antibiotics were administered
subcutaneously. The rats were placed in the prone position and
prepared in standard surgical fashion. L4–L5 posterolateral
fusions were performed [17, 18]. The spine was approached
(Wiltse approach) through a single midline skin incision and
two paramedian fascial incisions. The spinal level was deter-
mined with reference to the iliac crests. After exposure, the
transverse process was decorticated, bone graft was harvested
from both iliac crests, and fascial incisions were made over the
iliac crests. A rongeur was used to harvest approximately
0.1–0.2 cc of morselized corticocancellous bone from both
iliac crests. The wounds were irrigated, and the harvested graft
was placed into the fusion levels. We put the grafts under the
fascia of the paraspinal skeletal muscle after the fascia was
opened. Then the fascia was sutured. So the graft would remain
at the fusion site. At the same time, the rats were randomly
assigned to one of two groups: Group 1 rats underwent sham
operations on their necks (control group; n = 20); Group 2 rats
were implanted with TheraCyte-encapsulated 4 9 106 live
parathyroid cells into the subcutis of their necks (TheraCyte
group; n = 20). The Animal Use and Care Committee of our
hospital approved these procedures.
Preparation of PTH cells [14]
Parathyroid glands were obtained from patients who had
undergone surgery for symptomatic secondary hyperpara-
thyroidism. All parathyroid gland specimens were cut into
pieces and collected in Roswell Park Memorial Institute
(RPMI) solution (85 %), dimethyl sulfoxide (DMSO)
(10 %), and fetal calf serum (5 %). After step-freezing
to -79 C, specimens were stored in liquid nitrogen
(-197 C). Written informed consent was obtained from all
patients.
The parathyroid tissue was thawed in a 37 C water
bath, minced into small fragments in DMEM-f-12 medium
(Sigma Chemical, St. Louis, MO, USA), and digested for
2 h at 37 C in media containing collagenase II (1.2 mg/
ml; Sigma Chemical). After centrifugation at 500 g and
mechanical dispersion, the pellet was resuspended in
complete growth medium (DMEM-F-12) supplemented
with 5 % calf serum, 1 % Nutridoma-SP (Boehringer
Mannheim, Germany), 100 U penicillin/ml, 100 lg of
streptomycin/ml, 1 mM CaCl2 and 0.5 mM MgCl2, and the
suspension was filtered through 60- and 150-mesh screens.
The viability of the detached cells (trypsin/0.06 %
EDTA) was tested by the trypan blue method. A mixture of
1 ll of cells (density of 4 9 105/ml) and 5 ll trypan blue
was prepared, and then placed in a counting chamber to
determine the viability ratio (live cells/live ? dead cells).
TheraCyte implantable systems (Irvine, Calif.) were used
for cell encapsulation. The parathyroid cells were passed
through a 150-mesh screen, collected, and distributed, and
then suspended in RPMI solution at a density of 4 9 106 live
cells/ml for the TheraCyte group. Using the centrifugation
loading method according to the user’s manual (TheraCyte),
the TheraCyte-encapsulated live parathyroid cells were
implanted into the subcutaneous layer of the necks of the rats.
The TheraCyte device consists of an inner membrane of
polytetrafluoroethylene (PTFE) that is 30 lm thick and has a
0.4-lm pore size which prevents the entry of cells into the
device, while allowing the entry of antibodies and compli-
ment factors, and a laminated 15-lm thick PTFE outer
membrane which has a 5-lm pore size that allows improved
biocompatibility and induced vascularization. For the final
step, 4 9 106 cells in a volume of 1 ml were loaded into the
4.5-ll device (TheraCyte).
Killing and analysis
Six weeks after surgery, the lumbar spines were excised
and the fusion masses were examined. After inspection,
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manual palpation testing of the L4–L5 segment was per-
formed by three independent observers [17, 18]. Only
levels graded as solid by at least two observers were con-
sidered to be fused. Posteroanterior radiographs were
obtained for all specimens after the rats were killed. The
radiographs were viewed and graded as fused or not fused.
Representative specimens were fixed in 10 % neutral
formalin, decalcified, cut sagittally, then embedded in
paraffin, and stained with hematoxylin and eosin for
microscopic examination [19, 20]. Blood was drawn at the
time of implantation of the TheraCyte implantable system
and during killing to measure calcium, phosphorus, and
human iPTH levels.
Statistical analysis
Data were expressed as mean ± standard deviation. Sta-
tistical analysis was performed using repeated measures of
analysis of variance for iPTH, calcium, and phosphorus
levels. Fisher’s exact test (two-tailed) was used to deter-
mine if the proportion of rats judged as fused was signifi-
cantly greater in the TheraCyte group relative to the control
group. Comparison of trends in weight gain for the two
groups was performed using the one-tailed Student’s t test.
Significance was defined as P \ 0.05.
Results
Two rats expired due to anesthesia toxicity and two rats
were excluded from the study due to deep wound infection.
The final analysis included 18 rats in the control group and
18 rats in the TheraCyte group. The remaining rats toler-
ated the surgical procedure well and were ambulatory on
the following postoperative days. A trend in weight gain
was observed in the rats over time. The increase in body
weight for the control and TheraCyte experimental groups
was 36.2 ± 18.1 and 34.5 ± 17.1 g, respectively. How-
ever, at final examination, there was no significant differ-
ence in body weight between the two groups.
The explanted spines were assessed by manual palpation
(Table 1). Only levels graded as solid by at least two
Table 1 Fusion rates (manual palpation data for the control and
TheraCyte groups)
Control (%) TheraCyte (%)
Observer 1 7/18 (39) 14/18 (78)
Observer 2 7/18 (39) 13/18 (72)
Observer 3 6/18 (33) 11/18 (61)
All* 6/18 (33) 13/18 (72)
* Fisher’s exact test (two-tailed) was used to compare the two groups
(P = 0.044)
Fig. 1 The processes transversus (long arrow), facet joint (short
arrow), fused bony graft (arrow head) of lumbar area are highlighted
with arrows. Typical radiographs of a non-fusion, b partial fusion,
and c good fusion are presented
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observers were considered to be fused. Fusion was found in
6 of 18 rats (33 %) in the control group and 13 of 18 rats
(72 %) in the TheraCyte experimental group; the differ-
ence was statistically significant (P = 0.044). Assessment
of the evidence for bone fusion was difficult due to the
radiopacity of the rat skeletal system (Fig. 1). The radio-
graphic fusion rate for the control group was 11 % (2/18)
and for the TheraCyte group 50 % (9/18).
Fig. 2 The areas between grafted bony chip are highlighted with
arrows. Bridging trabeculae (a) with new bone formation (b) or
fibrous adhesion between bone graft chips (c and d) in the TheraCyte
group. Fibroadipose tissue and skeletal muscle separated bone graft
chips in the control group (e and f). Hematoxylin and eosin
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Histology analysis revealed bridging trabeculae or
fibrous adhesion bone graft chips in the fused specimens
(Fig. 2a–d). In the non-fused specimens, the bony islands
were widely separated by fibroadipose tissue and skeletal
muscle without bridging trabeculae or fibrous adhesion
between the graft chips (Fig. 2e, f). Overall, the results of
histology analysis were consistent with those of manual
palpation. Serum iPTH (pg/ml) levels were significantly
higher in the TheraCyte group than in the control group
(P \ 0.05). However, there was no significant difference
between the two groups in the level of serum calcium
(P = 0.118) or phosphorus (P = 0.143) (Table 2).
Discussion
Parathyroid hormone acts via PTH-1 receptors on osteo-
blasts and bone marrow stromal cells to induce osteoblastic
bone formation [19, 21, 22]. Its anabolic effects on the
skeleton have been well documented [23–25]. In animal
studies, PTH has been shown to facilitate facture healing
[7, 23] and increase the lumbar fusion rate [10, 11].
Although effective in the treatment of osteoporosis, daily
injection of PTH for a period of 1–2 years is required [8,
24, 26]. However, because daily injection of PTH is
inconvenient and troublesome, we used the implantation of
parathyroid tissue. In our previous study [14], following
implantation of TheraCyte-encapsulated 4 9 106 live
parathyroid cells in rats, we found that the parathyroid cells
can function very well and increase BMD in the lumbar
spine. It was thus hypothesized that the implantation of
TheraCyte-encapsulated parathyroid cells might enhance
the bone formation in the settings of fracture, non-unions,
and fusions. This animal study revealed more fusion in rats
that received implantation of TheraCyte-encapsulated
4 9 106 live parathyroid cells than in those rats that did not
(72 vs. 33 %). Serum levels of calcium and phosphorus
were not significantly different between the two groups. It
is presumed that the kidneys of the rats were functioning
normally and could keep serum calcium and phosphorus
levels within the normal range. Higher serum level of iPTH
in the TheraCyte group indicated good viability of the
implanted cells while the level was not high enough to
cause abnormal calcium concentration.
In the rats in our study, body weight at 6 weeks after
implantation was higher than that at baseline. However, the
differences between the two groups were not significant
and therefore the effect of body weight could be ignored.
Multiple means of fusion assessment have been used in
animal studies and fusion rates have differed among the
methods of analysis. Manual palpation has been proven to
be consistent and predictive of precise multidirectional
biomechanical testing in previous studies [18]. While his-
tology provides solid information about bone formation
and quality, it is possible that a gross error may miss the
bridging bone. Thus, we used manual palpation as the
standard to determine whether or not fusion had occurred
in this animal model [17, 18]. Radiographic examination
has been found to be notoriously poor for determining the
presence or absence of fusion in rats due to their small size
[17, 18, 27, 28]. In this animal study, we also had difficulty
correlating manual palpation results with radiographic
findings. In correlation with histology, it appeared that the
fibrous adhesion between cartilage was felt as solid fusion
on manual palpation while appearing as a gap between
implanted bony chips on radiography.
Posterolateral intertransverse process fusion is the
common type of surgical fusion performed in the lumbar
spine. The reported rate of non-union has ranged from 5 to
35 % [2, 29]. This fusion rate can be improved by systemic
medications [10, 11] or bone graft extenders, enhancer, and
substitutes [29]. In this rat posterolateral spinal fusion
model using the autologous bone graft the TheraCyte-
encapsulated live parathyroid cells significantly enhanced
posterolateral fusion success. Although the results are
encouraging, care must be taken when extrapolating these
results to human lumbar fusion. As with any animal study,
not all results seen in lower species are reproducible in
higher species. Further studies are needed to determine the
clinical significance. In conclusion, this pilot animal study
Table 2 Serum levels of calcium (mg/dl), phosphorus (mg/dl), and iPTH (pg/ml) at time of implantation and 6 weeks after TheraCyte
implantation
Serum level of calcium* Serum levels of phosphorus** Serum levels of iPTH***
Time of implantation 6 weeks Time of implantation 6 weeks Time of implantation 6 weeks
Control 10.3 ± 0.56 9.6 ± 1.22 5.3 ± 0.35 4.5 ± 0.77 5.45 ± 0.99 4.77 ± 2.1
TheraCyte 10.2 ± 0.55 10.3 ± 0.54 5.2 ± 0.845 5.5 ± 0.43 5.10 ± 1.98 9.3 ± 1.43
Values were obtained using repeated measures of analysis of variance. All data are presented as mean ± standard deviation
* P = 0.118
** P = 0.143
*** P \ 0.05
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revealed more fusions in rats that received TheraCyte-
encapsulated 4 9 106 live parathyroid cells without caus-
ing high serum calcium or low phosphorus concentrations.
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